Interobserver variability of size and density measurements on CT in patients with metastatic GISTS on imatinib mesylate (IM)

被引：1
|
作者：
Bulusu, V. R. [1 ]
Fawcett, S. [1 ]
Moyle, P. [1 ]
Carroll, N. [1 ]
机构：
[1] Addenbrookes Hosp, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.10563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10563
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Size does not matter! Patterns of response and progression in patients (PTS) with metastatic gastro intestinal stromal tumours (GISTS) on imatinib mesylate (IM)
    Bulusu, V
    Fawcett, S.
    Cook, N.
    Hatcher, H.
    Moyle, P.
    Carroll, N.
    Earl, H.
    Save, V
    Hardwick, R.
    Sherbourne, K.
    ANNALS OF ONCOLOGY, 2006, 17 : 100 - 100
  • [2] Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs)
    Byrd, D. M.
    Demetri, G. D.
    Joensuu, H.
    von Mehren, M.
    Heinrich, M.
    Eisenberg, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Does imatinib mesylate (IM) affect longterm outcome in patients with gastrointestinal stromal tumors (GISTs)?
    Jin, Judy
    Robinson, Ann
    Willis, Joseph
    Hardacre, Jeffrey
    Kim, Julian
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 205 (03) : S14 - S14
  • [4] Imatinib mesylate (IM) in locally advanced and metastatic gastrointestinal stromal tumours (GISTs): Cambridge GIST study group experience
    Bulusu, VR
    Basu, BJ
    Hatcher, H
    Parkinson, C
    Sherbourne, K
    Earl, HM
    Save, VE
    Carroll, NR
    Hardwick, RH
    Balan, K
    ANNALS OF ONCOLOGY, 2005, 16 : 311 - 311
  • [5] Efficacy imatinib mesylate and c-kit mutations in metastatic or unresectable GISTs
    Ryu, Min-Hee
    Kim, Taw Won
    Chang, Heung Moon
    Bang, Yung-Jue
    Kang, Won Ki
    Park, Joon Oh
    Park, Yeon Hee
    Shin, Dong Bok
    Lee, Kyung Hee
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
  • [6] Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+).
    Heinrich, MC
    Shoemaker, JS
    Corless, CL
    Hollis, D
    Demetri, GD
    Bertagnolli, MM
    Fletcher, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3S - 3S
  • [7] Imatinib discontinuation in patients with metastatic gastrointestinal stromal tumors (GISTs)
    de Pas, Tommaso
    Biffi, Roberto
    Mazzarol, Giovanni
    Della Vigna, Paolo
    Travaini, Laura
    Curigliano, Giuseppe
    Formica, Vincenzo
    de Braud, Filippo
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
  • [8] Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs
    Wang, Chunmeng
    Zheng, Biqiang
    Chen, Yong
    Cao, Xi
    Zhang, Ruming
    Shi, Yingqiang
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (01) : 63 - 70
  • [9] Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs
    Chunmeng Wang
    Biqiang Zheng
    Yong Chen
    Xi Cao
    Ruming Zhang
    Yingqiang Shi
    Chinese Journal of Cancer Research, 2013, 25 (01) : 63 - 70
  • [10] Intraobserver and interobserver variability in CT angiography and MR angiography measurements of the size of cerebral aneurysms
    Kim, Hye Jeong
    Yoon, Dae Young
    Kim, Eun Soo
    Lee, Hyung Jin
    Jeon, Hong Jun
    Lee, Jong Young
    Cho, Byung-Moon
    NEURORADIOLOGY, 2017, 59 (05) : 491 - 497
12345